An open, randomized, prospective, comparative study of topical pimecrolimus 1% cream and topical ketoconazole 2% cream in the treatment of seborrheic dermatitis

Journal of Dermatological Treatment

Volumn 20, Issue 1, 2009, Pages 4-9

  Koc, Erol ^a   Arca, Ercan ^a   Kose, Osman ^a   Akar, Ahmet ^a  

^a GULHANE SCHOOL OF MEDICINE   (Turkey)

Author keywords

Ketoconazole; Pimecrolimus; Seborrheic dermatitis; Treatment

Indexed keywords

KETOCONAZOLE; KETORAL; PIMECROLIMUS; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BURNING SENSATION; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERYTHEMA; FEMALE; FOLLOW UP; HUMAN; MALE; OPEN STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PRURITUS; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SEBORRHEIC DERMATITIS; SKIN INFILTRATE; SKIN IRRITATION;

ADULT; CHI-SQUARE DISTRIBUTION; DERMATITIS, SEBORRHEIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; KETOCONAZOLE; MALE; MIDDLE AGED; OINTMENTS; PATIENT SATISFACTION; PROBABILITY; PROSPECTIVE STUDIES; REFERENCE VALUES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TACROLIMUS; TREATMENT OUTCOME; TURKEY; YOUNG ADULT;

EID: 61649101534     PISSN: 09546634     EISSN: 14711753     Source Type: Journal    
DOI: 10.1080/09546630802286993     Document Type: Article

References (24)

1. Gupta AK, Bluhm R. Seborrheic dermatitis. J Eur Acad Dermatol Venereol. 2004;18:13-26.
2. Schwartz RA, Janusz CA, Janniger CK. Seborrheic dermatitis: An overview. Am Fam Physician. 2006;74:125-30.
3. Gupta AK, Medzia SE, Batra R. Etiology and management of seborrhoeic dermatitis. Dermatology. 2004;208:89-93.
4. Jonhson BA, Nunley JR. Treatment of seborrheic dermatitis. Am Fam Physician. 2000;61:2703-10.
5. Reichrath J. Antimycotics: Why are they effective in the treatment of seborrheic dermatitis? Dermatology. 2004;208:174-5.
6. Dobrev H, Zissova L. Effects of ketoconazole 2% shampoo on scalp sebum level in patients with seborrhoeic dermatitis. Acta Derm Venereol. 1997;77:132-4.
7. Pierard GE, Pierard-Franchimont C, vanCutsem J, Ruranginwa A, Hoppenbrouwers ML, Schrooten P. Ketoconazole 2% emulsion in the treatment of seborrhoeic dermatitis. Int J Dermatol. 1991;30:806-8.
8. Seckin D, Gurbuz O, Akin O. Metronidazole 0.75% gel vs. ketoconazole 2% cream in the treatment of facial seborrheic dermatitis: A randomized, double-blind study. J Eur Acad Dermatol Venereol. 2007;21:345-50.
9. Chosidow O, Maurette C, Dupuy P. Randomized, open-labeled, non-inferiority study between ciclopiroxolamine 1% cream and ketoconazole 2% foaming gel in mild to moderate facial seborrheic dermatitis. Dermatology. 2003;206:233-40.
10. Pierard-Franchimont C, Pierard GE. A double blind placebo controlled study of ketoconazole + desonide gel combination in the treatment of facial seborrheic dermatitis. Dermatology. 2002;204:344-7.
11. Dreno B, Chosidow O, Revuz J, Moyse D. Lithium gluconate 8% vs. ketoconazole 2% in the treatment of seborrhoeic dermatitis: A multicentre, randomized study. Br J Dermatol. 2003;148:1230-6.
12. Rallis E, Nasiopoulou A, Kouskoukis C, Koumantaki E. Pimecrolimus cream 1% can be an effective treatment for seborrheic dermatitis of the face and trunk. Drugs Exp Clin Res. 2004;30:191-5.
13. High WA, Pandya AG. Pilot trial of 1% pimecrolimus cream in the treatment of seborrheic dermatitis in African American adults with associated hypopigmentation. J Am Acad Dermatol. 2006;54:1083-8.
14. De Moraes AP, DeArruda EAG, Vitoriano MAV, De MoraesFilho MO, Bezerra FAF, Holanda EM, et al. An open-label efficacy pilot study with pimecrolimus cream 1% in adults with facial seborrhoeic dermatitis infected with HIV. J Eur Acad Dermatol Venereol. 2007;21:596-601.
15. Warshaw EM, Wohlhuter RS, Liu A, Zeller SA, Wenner RA, Bowers S, et al. Results of a randomized, double-blind, vehicle-controlled efficacy trial of pimecrolimus cream 1% for the treatment of moderate to severe facial seborrheic dermatitis. J Am Acad Dermatol. 2007;57:257-64.
16. Kim BS, Kim SH, Kim MB, Oh CK, Jang HS, Kwon KS. Treatment of facial seborrhoeic dermatitis with pimecrolimus cream 1%: An open-label clinical study in Korean patients. J Korean Med Sci. 2007;22:868-72.
17. Rigopoulos D, Ioannides D, Kalogeromitros D, Gregoriou S, Katsambas A. Pimecrolimus cream 1% vs. betamethasone 17-valerate 0.1% cream in the treatment of seborrheic dermatitis. A randomized open-label clinical trial. Br J Dermatol. 2004;151:1071-5.
18. Firooz A, Solhpour A, Gorouhi F, Daneshpazhooh M, Balighi K, Farsinejad K, et al. Pimecrolimus cream, 1%, vs. hydrocortone acetate cream, 1%, in the treatment of facial seborrheic dermatitis: A randomized, investigator-blind, clinical trial. Arch Dermatol. 2006;142:1066-7.
19. Crutchfield CE III. Pimecrolimus: A new treatment for seborrheic dermatitis. Cutis. 2002;70:207-8.
20. Brownell I, Quan LT, Hsu S. Topical pimecrolimus in the treatment of seborrheic dermatitis. Dermatol Online J. 2003;9:13.
21. Cunha PR. Pimecrolimus cream 1% is effective in seborrhoeic dermatitis refractory to treatment with topical corticosteroids. Acta Derm Venereol. 2006;86:69-70.
22. Koca R, Altinyazar C, Esturk E. Is topical metronidazole effective in seborrheic dermatitis? A double-blind study. Int J Dermatol. 2003;42:632-5.
23. Gisondi P, Ellis CN, Girolomoni G. Pimecrolimus in dermatology: Atopic dermatitis and beyond. Int J Clin Pract. 2005;59:969-74.
24. Ling MR. Topical tacrolimus and pimecrolimus: Future directions. Semin Cutan Med Surg. 2001;20:268-74.